Cargando…
Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study
Aim: This study aimed to evaluate the effectiveness and tolerability of intensifying the dose of canagliflozin from 100 mg/day (CANA100) to 300 mg/day (CANA300) in patients with type 2 diabetes (T2DM) and suboptimal metabolic control in a real-world setting. Methods: A multicenter observational stud...
Autores principales: | Gorgojo-Martinez, Juan J., Ferreira-Ocampo, Pablo José, Galdón Sanz-Pastor, Alba, Cárdenas-Salas, Jersy, Antón-Bravo, Teresa, Brito-Sanfiel, Miguel, Almodóvar-Ruiz, Francisca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342761/ https://www.ncbi.nlm.nih.gov/pubmed/37445283 http://dx.doi.org/10.3390/jcm12134248 |
Ejemplares similares
-
Predictive Factors of Renal Function Decline in Patients with Type 2 Diabetes Treated with Canagliflozin in the Real-Wecan Study
por: Gorgojo-Martinez, Juan J., et al.
Publicado: (2022) -
Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
por: Gorgojo-Martínez, Juan J., et al.
Publicado: (2020) -
Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States
por: Neslusan, Cheryl, et al.
Publicado: (2018) -
Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017) -
Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
por: Stafford, Sara, et al.
Publicado: (2022)